Tuesday June 11, 2024

From reactive to proactive: How data and prevention are re-shaping healthcare business models


The global push for a preventative versus reactive approach to healthcare combined with digital technology is altering the business model for all healthcare providers. Each has the opportunity to leverage their data to open up new revenue streams, cut costs and build better relationships with payors and directly with patients. For years lab service and hospital groups have sat on huge data repositories of valuable data but lacked the business models needed to turn this into something that could drive topline growth, until now. This session explores three business models that generate value from screening and routine testing and explores exactly how technology is enabling these models to be both scalable and sustainable.

Nelli Såger, Development Director, Mehiläinen
Prof Dr med Christian Schmidt, CEO, LifeLink Medical
Rick VanNess, Healthcare Executive and Laboratory Data Expert, Albuquerque, NM
Moderated by Dr Matthew Prime, Global Medical Director, Roche Diagnostic Information Solutions

Ballroom 1+2

Speakers


Rick VanNess
Rick VanNessHealthcare Executive and Laboratory Data ExpertAlbuquerque NM
Nelli Såger
Nelli SågerDevelopment DirectorMehiläinen
Prof Dr med Christian Schmidt
Prof Dr med Christian SchmidtCEOLifeLink Medical
Dr Matthew Prime
Dr Matthew PrimeHead of Healthcare Expertise & Evidence Generation Roche Information Solutions

Explore more sessions

View the agenda and see how this event will accelerate your business goals.

Explore similar sessions

11:30 amInvestment M&A

Healthcare – The new era for infrastructure investors

Healthcare’s stable and steady demand is attracting longer-term capital investors in infrastructure funds and family offices. So what does this new investor mean for the sector and for the businesses...

Ballroom 1+2

Davide Tavaniello
Davide TavanielloCo-CEOHippocrates
Rodolfo Guarino
Rodolfo GuarinoCo-CEOHippocrates
Assia Belkahia
Assia BelkahiaPartnerAntin Infrastructure Partners
Alberto Fernandez
Alberto FernandezCEOHealthcare Activos
Martin Henrichs
Martin HenrichsManaging Director - Head of Healthcare EMEAUBS
Read more

Healthcare – The new era for infrastructure investors


Healthcare’s stable and steady demand is attracting longer-term capital investors in infrastructure funds and family offices. So what does this new investor mean for the sector and for the businesses it is buying? What does value creation look like? How will this lead to the development of new delivery models and utilisation of community and urban space? This session featuring an Infrastructure investor and CEOs of infrastructure-owned providers includes a keynote from Italy’s Hippocrates Holdings. It will dive into the between this and other types of investors and discuss the opportunities in the market this new era heralds.

Keynote: Davide Tavaniello, Co-CEO, Hippocrates
Panellists:
Rodolfo Guarino, Co-CEO, Hippocrates
Assia Belkahia, Partner, Antin Infrastructure Partners
Alberto Fernandez, CEO, Healthcare Activos
Moderated by Martin Henrichs, Managing Director and Head of Healthcare EMEA, UBS

Ballroom 1+2

Speakers


Davide Tavaniello
Davide TavanielloCo-CEOHippocrates
Rodolfo Guarino
Rodolfo GuarinoCo-CEOHippocrates
Assia Belkahia
Assia BelkahiaPartnerAntin Infrastructure Partners
Alberto Fernandez
Alberto FernandezCEOHealthcare Activos
Martin Henrichs
Martin HenrichsManaging Director - Head of Healthcare EMEAUBS
2:50 pmSector Analysis

Laboratory diagnostics – Growth beyond consolidation

With few consolidation opportunities remaining, the future for labs lies in organic growth and digitalisation. What will be the impact of automation and smart laboratories? Will self-testing take off massively?...

Ballroom 3

Joe Stringer
Joe StringerExecutive ChairmanAutomata
Jean-François Pomerol
Jean-François PomerolChief Executive Officer & Co-FounderTribun Health
Jérôme Thill
Jérôme ThillPartnerHorasis Partners
Dr Stephan Rau
Dr Stephan RauPartnerMcDermott Will & Emery
Read more

Laboratory diagnostics – Growth beyond consolidation


With few consolidation opportunities remaining, the future for labs lies in organic growth and digitalisation. What will be the impact of automation and smart laboratories? Will self-testing take off massively? Is there a threat from blood testing start-ups that are like Theranos, but work? This session features three laboratory diagnostic CEOs who share their approaches to growth.

Speakers include:

Joe Stringer, Executive Chairman, Automata

Case Study: The future of automation in labs, Automata, and The Royal Marsden
With the demand for genomic testing on the back of screening programs exploding, how are lab groups managing to keep up? Lab automation group, Automata has enabled providers such as a The Royal Marsden NHS Trust to increase genomic test throughput by 3 to 5x whilst simultaneously halving the space required. In this case study Joe explains how this was possible, the future of innovation in laboratories, the impact on the scientific workforce and productivity, and why logistics is now the only significant barrier to scaling innovation.

Jean-Francois Pomerol, CEO & Co-Founder, Tribun Health
Jérôme Thill, Partner, Horasis
Moderated by Dr Stephan Rau, Partner, McDermott, Will & Emery

 

Ballroom 3

Speakers


Joe Stringer
Joe StringerExecutive ChairmanAutomata
Jean-François Pomerol
Jean-François PomerolChief Executive Officer & Co-FounderTribun Health
Jérôme Thill
Jérôme ThillPartnerHorasis Partners
Dr Stephan Rau
Dr Stephan RauPartnerMcDermott Will & Emery
10:00 amSector Analysis

Sector in focus: Ophthalmology

Ophthalmology continues to be a big area of investor interest with considerable scope for consolidation as national and international groups continue to develop. Governments are increasingly outsourcing cataract operations, new...

Ballroom 3

Volker Wendel
Volker WendelFounder and CEOSanoptis
Dr Michael Achtelik
Dr Michael AchtelikHead of Global Key AccountsCarl Zeiss Meditec AG
Peter Byloos
Peter ByloosCEOOptegra
Rens Schoenmakers
Rens SchoenmakersCEOFYEO
Tobias Koesters
Tobias KoestersPartnerL.E.K. Consulting
Read more

Sector in focus: Ophthalmology


Ophthalmology continues to be a big area of investor interest with considerable scope for consolidation as national and international groups continue to develop. Governments are increasingly outsourcing cataract operations, new drugs are being approved opening up bigger market potential and providers are developing new products and services to match patient demand. In this session providers and medtech discuss new models in care delivery, the impact of smart equipment and digital disruption and its impact on value creation.

Speakers include:

Volker Wendel, CEO, Sanoptis
Dr Michael Achtelik, Head of Global Key Accounts, Carl Zeiss Meditec
Peter Byloos, CEO, Optegra
Rens Schoenmakers, CEO, FYEO
Moderated by
Tobias Koesters, Partner, L.E.K.. Consulting

Ballroom 3

Speakers


Volker Wendel
Volker WendelFounder and CEOSanoptis
Dr Michael Achtelik
Dr Michael AchtelikHead of Global Key AccountsCarl Zeiss Meditec AG
Peter Byloos
Peter ByloosCEOOptegra
Rens Schoenmakers
Rens SchoenmakersCEOFYEO
Tobias Koesters
Tobias KoestersPartnerL.E.K. Consulting